

Supplementary material

Table 1 – Length of motor complexes (all control periods)

	Mean length	Count
Anterograde	114 ± 14	736
Retrograde	109 ± 18	458
Simultaneous	125 ± 17	13
All	116 ± 15	1207

Mean length in mm ± SEM; n = 30. See text for details

Table 2 – Propagation of motor complexes (physostigmine **control** period, n = 13)

	Small intestine	Colon	Full intestine	All MCs
Anterograde	128 (57%)	176 (64%)	40 (48%)	344 (59%)
Retrograde	91 (41%)	96 (35%)	44 (52%)	231 (40%)
Simultaneous	4 (2%)	2 (1%)	0 (0%)	6 (1%)
Total	223	274	84	581

Percentages refer to proportion within a column. See text for details.

Table 3 - Propagation of motor complexes (physostigmine **drug** period, n = 13)

	Small intestine	Colon	Full intestine	All MCs
Anterograde	85 (55%)	90 (60%)	51 (46%)	226 (54%)
Retrograde	70 (45%)	60 (40%)	58 (52%)	188 (45%)
Simultaneous	1 (1%)	1 (1%)	2 (2%)	4 (1%)
Total	156	151	111	418

Percentages refer to proportion within a column. See text for details

Table 4 – Counts and proportions of MCs in physostigmine versus control (n = 13)

	Control	Physostigmine
Small intestine	223 (38%)	156 (37%)
Colon	274 (47%)	151 (36%)
Full intestine	84 (15%)	111 (27%)
Total	581	418

Percentages refer to proportion within a column. See text for details.

Table 5 – Motor complex length – effect of physostigmine (n = 13)

	Control	Physostigmine	P (paired t-test)
Anterograde	116 ± 18	162 ± 25	0.073
Retrograde	116 ± 16	165 ± 26	0.064
Simultaneous	116 ± 24	180 ± 35	ND
All	116 ± 15	162 ± 25	0.070

Mean length in mm ± SEM; n = 13. ND, no data available for paired analysis. See text for details.